MALCOLM BRENNER to Humans
This is a "connection" page, showing publications MALCOLM BRENNER has written about Humans.
Connection Strength
1.289
-
Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma. J Immunother Cancer. 2023 01; 11(1).
Score: 0.017
-
Emerging Challenges to Cellular Therapy of Cancer. Cancer J. 2023 Jan-Feb 01; 29(1):20-27.
Score: 0.017
-
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820.
Score: 0.015
-
Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Cancer J. 2019 May/Jun; 25(3):199-207.
Score: 0.013
-
Adoptive Cell Therapy: ACT-Up or ACT-Out? Mol Ther. 2019 04 10; 27(4):693-694.
Score: 0.013
-
Onward and upward for immuno-oncology. Chin Clin Oncol. 2018 04; 7(2):18.
Score: 0.012
-
Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2.
Score: 0.012
-
Next Steps in the CAR Journey of a Thousand Miles. Mol Ther. 2017 10 04; 25(10):2226-2227.
Score: 0.012
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.011
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.011
-
Immunotherapy against cancer-related viruses. Cell Res. 2017 Jan; 27(1):59-73.
Score: 0.011
-
Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016 Nov; 44(11):1013-1019.
Score: 0.011
-
Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31.
Score: 0.010
-
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy. Stem Cell Reports. 2015 Oct 13; 5(4):597-608.
Score: 0.010
-
CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83.
Score: 0.010
-
Severe congenital malformations, family functioning and parents' separation/divorce: a longitudinal study. Child Care Health Dev. 2016 Jan; 42(1):16-24.
Score: 0.010
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.010
-
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
Score: 0.010
-
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
Score: 0.010
-
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
Score: 0.010
-
iCaspase 9 Suicide Gene System. Methods Mol Biol. 2015; 1317:87-105.
Score: 0.010
-
A question of reproducibility. Mol Ther. 2014 Dec; 22(12):2015.
Score: 0.010
-
Gene-modified cells for stem cell transplantation and cancer therapy. Hum Gene Ther. 2014 Jul; 25(7):563-9.
Score: 0.009
-
Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
Score: 0.009
-
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan; 257(1):107-26.
Score: 0.009
-
CAR T cells for acute myeloid leukemia: the LeY of the land. Mol Ther. 2013 Nov; 21(11):1983-4.
Score: 0.009
-
Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct; 14(11):e447-e456.
Score: 0.009
-
Introducing molecular therapy--methods & clinical development. Mol Ther. 2013 Jun; 21(6):1105.
Score: 0.009
-
Introducing a new ASGCT forum for publication of methodology and clinical development in gene, cell, and oligonucleotide therapies. Mol Ther. 2012 Nov; 20(11):2005-6.
Score: 0.008
-
Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther. 2012 Dec; 19(12):818-21.
Score: 0.008
-
Personalized medicine: words that mean just what you choose? Mol Ther. 2012 Feb; 20(2):241-2.
Score: 0.008
-
Cellular therapy for cancer: let there be light. Tissue Antigens. 2012 Jan; 79(1):1-3.
Score: 0.008
-
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
Score: 0.008
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.008
-
Stemming our irrational exuberance. Mol Ther. 2011 Aug; 19(8):1399-400.
Score: 0.008
-
Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011 Oct; 13(9):1128-39.
Score: 0.008
-
Clinical success of complex biological therapies: be careful what you wish for... Mol Ther. 2010 Oct; 18(10):1737-8.
Score: 0.007
-
T cell receptors and cancer: gain gives pain. Nat Med. 2010 May; 16(5):520-1.
Score: 0.007
-
The eyes have it. Mol Ther. 2010 Mar; 18(3):451-2.
Score: 0.007
-
Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
Score: 0.007
-
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010 Mar; 24(3):563-72.
Score: 0.007
-
Cellular immunotherapy of cancer. Methods Mol Biol. 2010; 651:319-45.
Score: 0.007
-
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009 Nov 18; 8:106.
Score: 0.007
-
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov; 20(11):1229-39.
Score: 0.007
-
Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des. 2009; 15(4):424-9.
Score: 0.006
-
Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009; 675-81.
Score: 0.006
-
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
Score: 0.006
-
The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1.
Score: 0.006
-
Developing T-cell therapies for cancer in an academic setting. Adv Exp Med Biol. 2008; 610:88-99.
Score: 0.006
-
T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007 Nov; 14(6):616-24.
Score: 0.006
-
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24.
Score: 0.006
-
The continuing contribution of gene marking to cell and gene therapy. Mol Ther. 2007 Apr; 15(4):666-76.
Score: 0.006
-
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006 Oct; 20(10):1819-28.
Score: 0.005
-
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
Score: 0.005
-
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23.
Score: 0.005
-
Vaccine therapies for pediatric malignancies. Cancer J. 2005 Jul-Aug; 11(4):331-9.
Score: 0.005
-
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
Score: 0.005
-
A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 2005 Feb; 4(2):203-5.
Score: 0.005
-
Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy. 2005; 7(2):116-25.
Score: 0.005
-
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood. 2005 Mar 15; 105(6):2436-42.
Score: 0.005
-
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33.
Score: 0.005
-
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.
Score: 0.005
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
Score: 0.005
-
Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004 Jul; 10(1):5-18.
Score: 0.005
-
Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential. Best Pract Res Clin Haematol. 2004 Jun; 17(2):359-74.
Score: 0.005
-
Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460.
Score: 0.005
-
Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004 Oct 15; 104(8):2272-80.
Score: 0.005
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.005
-
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 Jun; 5(6):880-894.
Score: 0.005
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.005
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
Score: 0.005
-
Antigen-induced regulatory T cells. Blood. 2004 Jul 01; 104(1):26-33.
Score: 0.005
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
Score: 0.005
-
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood. 2003 Nov 15; 102(10):3815-21.
Score: 0.004
-
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.
Score: 0.004
-
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
Score: 0.004
-
Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
Score: 0.004
-
Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
Score: 0.004
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
Score: 0.004
-
Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
Score: 0.004
-
Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
Score: 0.004
-
Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 2003; 110(2-3):154-9.
Score: 0.004
-
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
Score: 0.004
-
Cancer vaccines: dream, reality, or nightmare? Clin Exp Med. 2002 Nov; 2(3):109-18.
Score: 0.004
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
Score: 0.004
-
Evidence-based regulation--a personal view. Mol Ther. 2002 Aug; 6(2):137.
Score: 0.004
-
Response to "systemic adenovirus delivery". Mol Ther. 2002 Aug; 6(2):138.
Score: 0.004
-
Targeting glycans for CAR therapy: The advent of sweet CARs. Mol Ther. 2022 09 07; 30(9):2881-2890.
Score: 0.004
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.004
-
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16.
Score: 0.004
-
Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41.
Score: 0.004
-
Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001 Oct 15; 94(2):228-36.
Score: 0.004
-
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
Score: 0.004
-
Cancer vaccines. Hematol Oncol Clin North Am. 2001 Aug; 15(4):741-73.
Score: 0.004
-
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
Score: 0.004
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.004
-
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001 May; 8(5):378-87.
Score: 0.004
-
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70.
Score: 0.004
-
Gene transfer and the treatment of haematological malignancy. J Intern Med. 2001 Apr; 249(4):345-58.
Score: 0.004
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.
Score: 0.004
-
Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001 Mar 01; 97(5):1227-31.
Score: 0.004
-
Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272.
Score: 0.004
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.004
-
Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001 Jan; 27(1):117-20.
Score: 0.004
-
Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
Score: 0.004
-
Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):692-5.
Score: 0.004
-
To be or notch to be. Nat Med. 2000 Nov; 6(11):1210-1.
Score: 0.004
-
Transgenic CD8a? co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells. J Immunother Cancer. 2020 11; 8(2).
Score: 0.004
-
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
Score: 0.004
-
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
Score: 0.004
-
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.
Score: 0.004
-
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
Score: 0.004
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.004
-
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8a?-engineered human CD4+ T cells. Sci Adv. 2020 07; 6(27):eaaz7809.
Score: 0.004
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.004
-
Adoptive therapy of posttransplant lymphoma. Cancer J. 2000 May; 6 Suppl 3:S259-64.
Score: 0.003
-
Reports of adenovector "death" are greatly exaggerated. Mol Ther. 2000 Mar; 1(3):205.
Score: 0.003
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.003
-
Gene transfer by adenovectors. Blood. 1999 Dec 15; 94(12):3965-7.
Score: 0.003
-
"Resistance is futile". Gene Ther. 1999 Oct; 6(10):1646-7.
Score: 0.003
-
Cure of leukemia. Semin Hematol. 1999 Oct; 36(4 Suppl 7):73-83.
Score: 0.003
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.003
-
Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
Score: 0.003
-
"The end of the beginning": molecular and cellular biology of gene therapy keystone. 14-20 January 1999. Biochim Biophys Acta. 1999 Jul 29; 1424(1):R5-9.
Score: 0.003
-
Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun; 23(6):549-57.
Score: 0.003
-
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999 Mar; 5(3):309-13.
Score: 0.003
-
Fifth annual ISHAGE meeting - Oslo 1999. Cytotherapy. 1999; 1(3):163.
Score: 0.003
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.003
-
Use of gene marking technologies in oncology. Forum (Genova). 1998 Oct-Dec; 8(4):342-53.
Score: 0.003
-
EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
Score: 0.003
-
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998 Sep 15; 92(6):1941-9.
Score: 0.003
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.003
-
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. Clin Cancer Res. 2018 12 15; 24(24):6185-6194.
Score: 0.003
-
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998 Jun 10; 9(9):1303-11.
Score: 0.003
-
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987.
Score: 0.003
-
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34.
Score: 0.003
-
High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650.
Score: 0.003
-
Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
Score: 0.003
-
BMT beats autoimmune disease. Nat Med. 1998 Feb; 4(2):153-5.
Score: 0.003
-
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
Score: 0.003
-
Applications of gene transfer in hematologic malignancy. Recent Results Cancer Res. 1998; 144:60-9.
Score: 0.003
-
Gene transfer and the treatment of childhood cancer. Cancer Invest. 1998; 16(4):269-78.
Score: 0.003
-
Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
Score: 0.003
-
EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8.
Score: 0.003
-
Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
Score: 0.003
-
c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood. 2017 12 21; 130(25):2739-2749.
Score: 0.003
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.003
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.003
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.003
-
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
Score: 0.003
-
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
Score: 0.003
-
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
Score: 0.003
-
Hematological malignancies. FASEB J. 1997 Jul; 11(8):640-8.
Score: 0.003
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.003
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.003
-
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
Score: 0.003
-
A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood. 1997 Jan 01; 89(1):119-27.
Score: 0.003
-
Emerging applications of gene transfer in the hematopoietic cancers. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):1-6.
Score: 0.003
-
Gene transfer in haematological malignancy. Ann Med. 1996 Dec; 28(6):491-7.
Score: 0.003
-
Gene marking. Hum Gene Ther. 1996 Oct 20; 7(16):1927-36.
Score: 0.003
-
Gene marking and gene therapy for transplantation medicine. J Hematother. 1996 Oct; 5(5):553-5.
Score: 0.003
-
Placental blood transplant: who will benefit? Nat Med. 1996 Sep; 2(9):969-70.
Score: 0.003
-
Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200.
Score: 0.003
-
A whole blood model of thrombocytopenia that controls platelet count and hematocrit. Ann Hematol. 2016 Oct; 95(11):1887-94.
Score: 0.003
-
Gene transfer to hematopoietic cells. N Engl J Med. 1996 Aug 01; 335(5):337-9.
Score: 0.003
-
Gene transfer and therapeutic drug monitoring. Ther Drug Monit. 1996 Aug; 18(4):322-7.
Score: 0.003
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.003
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.003
-
Gene marking. Gene Ther. 1996 Apr; 3(4):278-9.
Score: 0.003
-
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016 Jun; 24(6):1135-1149.
Score: 0.003
-
3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 2016 Apr; 84:76-85.
Score: 0.003
-
Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13.
Score: 0.003
-
Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
Score: 0.003
-
Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
Score: 0.003
-
Autologous bone-marrow transplantation in childhood acute lymphoblastic leukaemia. Lancet. 1995 Sep 30; 346(8979):856-7.
Score: 0.003
-
The contribution of marker gene studies to hemopoietic stem cell therapies. Stem Cells. 1995 Sep; 13(5):453-61.
Score: 0.003
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.002
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.002
-
Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
Score: 0.002
-
Human somatic gene therapy: progress and problems. J Intern Med. 1995 Mar; 237(3):229-39.
Score: 0.002
-
The use of cytokines to improve gene transfer to human hematopoietic stem cells. Cytokines Mol Ther. 1995 Mar; 1(1):3-9.
Score: 0.002
-
Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91.
Score: 0.002
-
Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994 Dec; 1(4):253-8.
Score: 0.002
-
Genetic marking and manipulation of hematopoietic progenitor cells using retroviral vectors. Immunomethods. 1994 Dec; 5(3):204-10.
Score: 0.002
-
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
Score: 0.002
-
Current status of gene transfer into haemopoietic progenitor cells: application to Langerhans cell histiocytosis. Br J Cancer Suppl. 1994 Sep; 23:S56-7.
Score: 0.002
-
Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994 Jul 15; 84(2):380-3.
Score: 0.002
-
Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
Score: 0.002
-
Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci. 1994 May 31; 716:204-14; discussion 214-5, 225-7.
Score: 0.002
-
Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone Marrow Transplant. 2014 Jul; 49(7):986-7.
Score: 0.002
-
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
Score: 0.002
-
Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
Score: 0.002
-
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138.
Score: 0.002
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
Score: 0.002
-
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25.
Score: 0.002
-
Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
Score: 0.002
-
Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6.
Score: 0.002
-
Gene marking to improve the outcome of autologous bone marrow transplantation. Prog Clin Biol Res. 1994; 389:587-91.
Score: 0.002
-
Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother. 1994; 3(1):33-6.
Score: 0.002
-
Speech measures indicating workload demand. Aviat Space Environ Med. 1994 Jan; 65(1):21-6.
Score: 0.002
-
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
Score: 0.002
-
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
Score: 0.002
-
Engineered T cells for cancer treatment. Cytotherapy. 2014 Jun; 16(6):713-33.
Score: 0.002
-
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7.
Score: 0.002
-
Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
Score: 0.002
-
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014 Jan 01; 20(1):131-9.
Score: 0.002
-
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
Score: 0.002
-
TNF and chronic B lymphoproliferative disorders. Leukemia. 1993 Sep; 7(9):1476.
Score: 0.002
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.002
-
Mouse models in bone marrow transplantation and adoptive cellular therapy. Semin Hematol. 2013 Apr; 50(2):131-44.
Score: 0.002
-
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013 Sep; 20(9):958-62.
Score: 0.002
-
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May; 67(5):933-8.
Score: 0.002
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.002
-
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993 Jan 09; 341(8837):85-6.
Score: 0.002
-
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):123-31, S1.
Score: 0.002
-
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76.
Score: 0.002
-
Gene transfer into human hematopoietic progenitor cells: a review of current clinical protocols. J Hematother. 1993; 2(1):7-17.
Score: 0.002
-
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993 Jan 01; 177(1):213-8.
Score: 0.002
-
Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant. 1993 Jan; 11(1):33-6.
Score: 0.002
-
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18.
Score: 0.002
-
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013 Jan 01; 19(1):106-17.
Score: 0.002
-
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32.
Score: 0.002
-
Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1). Blood. 1992 Jun 01; 79(11):3059-66.
Score: 0.002
-
Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol. 1992 Jun; 81(2):231-4.
Score: 0.002
-
An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood. 1992 May 15; 79(10):2694-700.
Score: 0.002
-
Cell-specific transmembrane injection of molecular cargo with gold nanoparticle-generated transient plasmonic nanobubbles. Biomaterials. 2012 Jul; 33(21):5441-50.
Score: 0.002
-
Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther. 1992 Apr; 3(2):129-36.
Score: 0.002
-
IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8.
Score: 0.002
-
Immunotherapy of leukemia. Leukemia. 1992; 6 Suppl 1:76-9.
Score: 0.002
-
Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
Score: 0.002
-
Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
Score: 0.002
-
Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
Score: 0.002
-
GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology. 2011 Sep 27; 77(13):1287-94.
Score: 0.002
-
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
Score: 0.002
-
Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep; 28(6):459-60.
Score: 0.002
-
Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol. 1991 Jul; 4(3):727-49.
Score: 0.002
-
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
Score: 0.002
-
Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function. Blood. 1991 Mar 15; 77(6):1283-9.
Score: 0.002
-
IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation. Bone Marrow Transplant. 1991 Feb; 7(2):81-7.
Score: 0.002
-
IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma. Immunology. 1991 Feb; 72(2):161-6.
Score: 0.002
-
Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. Transplant Proc. 1991 Feb; 23(1 Pt 2):1704-5.
Score: 0.002
-
Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol. 1991 Feb; 77(2):237-44.
Score: 0.002
-
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62.
Score: 0.002
-
Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51.
Score: 0.002
-
Genetic modification of T cells. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S15-20.
Score: 0.002
-
CMV-induced augmentation of GVL effect may be mediated by cytokines. Bone Marrow Transplant. 1991 Jan; 7(1):69.
Score: 0.002
-
Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients. Blood. 1990 Dec 15; 76(12):2470-5.
Score: 0.002
-
Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990 Dec 01; 172(6):1729-34.
Score: 0.002
-
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90.
Score: 0.002
-
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
Score: 0.002
-
Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990 Sep 01; 76(5):1046-53.
Score: 0.002
-
Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010 Sep; 12(5):576-8.
Score: 0.002
-
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
Score: 0.002
-
Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol. 1990 Aug; 75(4):499-505.
Score: 0.002
-
An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15.
Score: 0.002
-
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
Score: 0.002
-
Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70.
Score: 0.002
-
The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81.
Score: 0.002
-
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
Score: 0.002
-
Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol. 1990 Jan 15; 144(2):541-7.
Score: 0.002
-
Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol. 1989 Dec 01; 143(11):3828-34.
Score: 0.002
-
Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol. 1989 Dec; 73(4):468-74.
Score: 0.002
-
Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42.
Score: 0.002
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.002
-
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther. 2009 Oct; 9(5):396-408.
Score: 0.002
-
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
Score: 0.002
-
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60.
Score: 0.002
-
Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20.
Score: 0.002
-
In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep; 74(4):1374-80.
Score: 0.002
-
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92.
Score: 0.002
-
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
Score: 0.002
-
Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol. 1989 Jun; 72(2):122-6.
Score: 0.002
-
Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. J Immunother. 2009 Jun; 32(5):524-38.
Score: 0.002
-
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
Score: 0.002
-
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
Score: 0.002
-
Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
Score: 0.002
-
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
Score: 0.002
-
Current role and status of bone marrow transplantation. Br J Hosp Med. 1989 Mar; 41(3):260-5.
Score: 0.002
-
A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008 Nov-Dec; 31(9):812-9.
Score: 0.002
-
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
Score: 0.002
-
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
Score: 0.002
-
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
Score: 0.002
-
Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008 Oct 21; 71(17):1326-34.
Score: 0.002
-
Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis. Br J Haematol. 1988 Sep; 70(1):37-41.
Score: 0.002
-
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
Score: 0.002
-
Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2008 Sep; 21(3):375-89.
Score: 0.002
-
Differential recovery of phenotypically and functionally distinct circulating antigen-presenting cells after allogeneic marrow transplantation. Transplantation. 1988 Jun; 45(6):1084-91.
Score: 0.002
-
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
Score: 0.002
-
In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. J Immunol. 1988 May 15; 140(10):3461-6.
Score: 0.002
-
Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30; 1(8592):969-71.
Score: 0.002
-
Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther. 2008 Mar; 16(3):599-606.
Score: 0.001
-
Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. Nouv Rev Fr Hematol (1978). 1988; 30(5-6):317-9.
Score: 0.001
-
Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. Cytotherapy. 2008; 10(5):526-39.
Score: 0.001
-
Interleukin 2 enhances cytotoxic cell function in vitro after T-cell depleted marrow transplantation. Br J Haematol. 1987 Nov; 67(3):273-9.
Score: 0.001
-
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther. 2007 Nov; 14(22):1555-63.
Score: 0.001
-
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54.
Score: 0.001
-
[Therapeutic advances in bone marrow transplantation]. Clin Ter. 1987 Sep 15; 122(5):321-32.
Score: 0.001
-
Regeneration of humoral immunity to herpes simplex virus following T-cell-depleted allogeneic bone marrow transplantation. J Med Virol. 1987 Sep; 23(1):93-9.
Score: 0.001
-
Cytomegalovirus pneumonitis after allogeneic marrow transplantation. Lancet. 1987 Aug 01; 2(8553):286-7.
Score: 0.001
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.001
-
Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6.
Score: 0.001
-
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
Score: 0.001
-
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
Score: 0.001
-
Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections. Lancet. 1987 Apr 04; 1(8536):774-6.
Score: 0.001
-
Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
Score: 0.001
-
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol. 2007 Feb; 170(2):620-32.
Score: 0.001
-
Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007 Feb-Mar; 30(2):227-33.
Score: 0.001
-
Bone marrow transplantation in acute or chronic leukaemia. Acta Haematol. 1987; 78 Suppl 1:194-7.
Score: 0.001
-
Human large granular lymphocytes induce immunoglobulin synthesis after bone marrow transplantation. Eur J Immunol. 1987 Jan; 17(1):43-7.
Score: 0.001
-
Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
Score: 0.001
-
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
Score: 0.001
-
The contribution of large granular lymphocytes to B cell activation and differentiation after T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1986 Sep; 42(3):257-61.
Score: 0.001
-
Recovery of immunoglobulin isotypes following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Sep; 64(1):125-32.
Score: 0.001
-
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
Score: 0.001
-
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9.
Score: 0.001
-
CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94.
Score: 0.001
-
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60.
Score: 0.001
-
Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52.
Score: 0.001
-
The use of monoclonal antibodies in graft versus host disease prevention. Haematologia (Budap). 1986; 19(3):167-76.
Score: 0.001
-
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother. 2006 Jan-Feb; 29(1):21-31.
Score: 0.001
-
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7.
Score: 0.001
-
T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
Score: 0.001
-
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802.
Score: 0.001
-
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41.
Score: 0.001
-
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41.
Score: 0.001
-
An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
Score: 0.001
-
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005 Jun 15; 105(12):4677-84.
Score: 0.001
-
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33.
Score: 0.001
-
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42.
Score: 0.001
-
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 01; 105(5):1898-904.
Score: 0.001
-
The role of B cell differentiation factors and specific T cell help in the pathogenesis of primary hypogammaglobulinemia. Eur J Immunol. 1984 Nov; 14(11):1021-7.
Score: 0.001
-
E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther. 2004 Sep; 11(9):585-93.
Score: 0.001
-
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40.
Score: 0.001
-
Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
Score: 0.001
-
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
Score: 0.001
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.001
-
Non-specific factor enhancement of human in vitro antigen-dependent antibody synthesis: role of B cell activation and T cell help. Immunology. 1984 Apr; 51(4):783-91.
Score: 0.001
-
An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res. 2004 Mar; 28(3):295-9.
Score: 0.001
-
Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008.
Score: 0.001
-
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004 Feb 16; 199(4):459-70.
Score: 0.001
-
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91.
Score: 0.001
-
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
Score: 0.001
-
The interaction of specific T-cell help and non-specific B-cell growth factors in the production of anti-tetanus antibody by human B cells grown in serum-free microcultures. Immunology. 1983 Nov; 50(3):377-85.
Score: 0.001
-
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004 Feb 01; 103(3):1011-9.
Score: 0.001
-
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. J Virol. 2003 Oct; 77(20):10872-80.
Score: 0.001
-
Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 2003 Sep 01; 63(17):5213-7.
Score: 0.001
-
American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther. 2003 Aug; 8(2):180-7.
Score: 0.001
-
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54.
Score: 0.001
-
Human B cell growth factors overcome T cell-mediated inhibition of specific antibody production: a possible mechanism for the exacerbation of autoimmune disease. Clin Exp Immunol. 1983 Jun; 52(3):635-40.
Score: 0.001
-
Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56.
Score: 0.001
-
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003 Apr 10; 14(6):545-59.
Score: 0.001
-
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
Score: 0.001
-
[Gene therapy of childhood cancers: current status and perspectives]. Bull Cancer. 2003 Mar; 90(3):227-38.
Score: 0.001
-
Induction of immunoglobulin and antigen-dependent antibody synthesis in human lymphocytes, using supernatants from mitogen-stimulated cultures. Immunology. 1983 Jan; 48(1):157-63.
Score: 0.001
-
Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40.
Score: 0.001
-
Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9.
Score: 0.001
-
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.
Score: 0.001
-
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood. 2003 Feb 01; 101(3):1007-14.
Score: 0.001
-
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
Score: 0.001
-
Molecular findings in symptomatic and pre-symptomatic Alexander disease patients. Neurology. 2002 May 28; 58(10):1494-500.
Score: 0.001
-
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87.
Score: 0.001
-
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 2002 Feb 15; 62(4):1123-8.
Score: 0.001
-
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18.
Score: 0.001
-
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33.
Score: 0.001
-
Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4.
Score: 0.001
-
Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42.
Score: 0.001
-
Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol. 2002; 81 Suppl 2:S42-3.
Score: 0.001
-
Human anti-tetanus antibody response in vitro: autologous and allogeneic T cells provide help by different routes. Clin Exp Immunol. 1981 Oct; 46(1):171-7.
Score: 0.001
-
hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis. 2001 Oct; 31(2):85-94.
Score: 0.001
-
Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001 Sep 27; 72(6):1078-86.
Score: 0.001
-
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
Score: 0.001
-
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 Aug 15; 98(4):1166-73.
Score: 0.001
-
Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7.
Score: 0.001
-
Impact of a multidisciplinary day program on disease and healthcare costs in children and adolescents with severe asthma: a two-year follow-up study. Pediatr Pulmonol. 2001 Mar; 31(3):177-89.
Score: 0.001
-
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43.
Score: 0.001
-
T-cell help in human in vitro antibody-producing systems: role of inhibitory T cells in masking allogeneic help. Cell Immunol. 1981 Jan 01; 57(1):201-8.
Score: 0.001
-
Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9.
Score: 0.001
-
Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
Score: 0.001
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.001
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 2000 Apr 10; 11(6):919-79.
Score: 0.001
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.001
-
Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther. 2000 Feb; 1(2):171-9.
Score: 0.001
-
Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. J Clin Immunol. 2000 Jan; 20(1):1-9.
Score: 0.001
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1999 Dec 10; 10(18):3067-123.
Score: 0.001
-
Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999 Oct; 24(7):735-9.
Score: 0.001
-
Retinoblastoma treatment. Science. 1999 Jul 30; 285(5428):663-4.
Score: 0.001
-
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. Life Sci. 1999; 65(5):483-91.
Score: 0.001
-
Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999; 14(3):154-6.
Score: 0.001
-
Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. Cytotherapy. 1999; 1(6):433-8.
Score: 0.001
-
Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene. Cancer Res. 1998 Oct 15; 58(20):4577-80.
Score: 0.001
-
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
Score: 0.001
-
Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J Hematother. 1998 Jun; 7(3):217-24.
Score: 0.001
-
Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.
Score: 0.001
-
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998 Apr 15; 91(8):2925-34.
Score: 0.001
-
Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr; 12(2):339-57.
Score: 0.001
-
Expression of the human immunodeficiency virus type 1 primer binding sequence inhibits HIV-1 replication. Hum Gene Ther. 1998 Mar 01; 9(4):587-90.
Score: 0.001
-
Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression. Bone Marrow Transplant. 1998 Jan; 21(1):73-8.
Score: 0.001
-
Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93.
Score: 0.001
-
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
Score: 0.001
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38.
Score: 0.001
-
Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997 Sep 13; 350(9080):767-71.
Score: 0.001
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313.
Score: 0.001
-
Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood. 1996 Nov 01; 88(9):3329-35.
Score: 0.001
-
Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996 Oct; 23(3-4):213-20.
Score: 0.001
-
Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47.
Score: 0.001
-
High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum Gene Ther. 1996 Jun 20; 7(10):1233-9.
Score: 0.001
-
Gene therapy: socioeconomic and ethical issues. A roundtable discussion. Hum Gene Ther. 1996 Jun 10; 7(9):1139-44.
Score: 0.001
-
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5.
Score: 0.001
-
Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67.
Score: 0.001
-
Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
Score: 0.001
-
Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. 1995 Dec; 2(4):291-7.
Score: 0.001
-
Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
Score: 0.001
-
Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep; 6(9):1231-55.
Score: 0.001
-
Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. Bone Marrow Transplant. 1995 Jun; 15(6):829-35.
Score: 0.001
-
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
Score: 0.001
-
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
Score: 0.001
-
European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
Score: 0.001
-
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
Score: 0.001
-
Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 08; 331(10):679-80.
Score: 0.001
-
XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
Score: 0.001
-
Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97.
Score: 0.001
-
Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 Feb; 13(2):221-3.
Score: 0.001
-
Concentric sclerosis (Bal?): morphometric and in situ hybridization study of lesions in six patients. Ann Neurol. 1994 Jan; 35(1):18-30.
Score: 0.001
-
Transfer of humoral immunity against cytomegalovirus proteins following transplantation of T-cell-depleted allogeneic bone marrow from seropositive donors. J Med Virol. 1993 Oct; 41(2):150-8.
Score: 0.001
-
Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8.
Score: 0.001
-
Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer. 1993 Jul 15; 72(2):623-8.
Score: 0.001
-
Measurement of red blood cell-vitamin B12: a study of the correlation between intracellular B12 content and concentrations of plasma holotranscobalamin II. Am J Hematol. 1993 Jul; 43(3):226-9.
Score: 0.001
-
Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT. Bone Marrow Transplant. 1992 Dec; 10(6):521-7.
Score: 0.001
-
Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. Bone Marrow Transplant. 1992 Nov; 10(5):457-62.
Score: 0.001
-
Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992 Apr; 3(2):137-45.
Score: 0.000
-
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia. 1992; 6 Suppl 2:39-43.
Score: 0.000
-
Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Br J Haematol. 1991 Oct; 79 Suppl 1:14-6.
Score: 0.000
-
Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant. 1991 Jul; 8(1):19-26.
Score: 0.000
-
Molecular analysis of retroviral transduction in chronic myelogenous leukemia. Hum Gene Ther. 1991; 2(4):317-21.
Score: 0.000
-
A downstream initiation element required for efficient TATA box binding and in vitro function of TFIID. Nature. 1990 Nov 01; 348(6296):86-8.
Score: 0.000
-
Transfection and gene expression in normal and malignant primary B lymphocytes. J Immunol Methods. 1990 Oct 04; 133(1):77-85.
Score: 0.000
-
Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. Transplantation. 1990 Mar; 49(3):547-53.
Score: 0.000
-
Origin of marrow stromal cells and haemopoietic chimaerism following bone marrow transplantation determined by in situ hybridisation. Br J Cancer. 1990 Mar; 61(3):385-9.
Score: 0.000
-
A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989 Oct 19; 321(16):1061-8.
Score: 0.000
-
A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer. 1989 Oct; 60(4):610-5.
Score: 0.000
-
Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia. 1989 Sep; 3(9):631-6.
Score: 0.000
-
Rapid expression of protooncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore. Blood. 1989 May 01; 73(6):1656-63.
Score: 0.000
-
A comparison of double beta-lactam combinations with netilmicin/ureidopenicillin regimens in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother. 1989 May; 23(5):759-71.
Score: 0.000
-
Do double-beta-lactam combinations prolong neutropenia in patients undergoing chemotherapy or bone marrow transplantation for hematological disease? Antimicrob Agents Chemother. 1989 Apr; 33(4):503-7.
Score: 0.000
-
Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989 Mar; 4(2):207-8.
Score: 0.000
-
Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol. 1989 Feb; 27(2):117-9.
Score: 0.000
-
Prolonged remission of Epstein-Barr virus associated lymphoma secondary to T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1988 Nov; 3(6):641-6.
Score: 0.000
-
Surface expression of only gamma delta and/or alpha beta T cell receptor heterodimers by cells with four (alpha, beta, gamma, delta) functional receptor chains. J Exp Med. 1988 Sep 01; 168(3):1003-20.
Score: 0.000
-
Expression of tartrate-resistant acid phosphatase in B-CLL treated with phorbol ester or phorbol ester plus calcium ionophore. Eur J Haematol. 1988 Sep; 41(3):250-7.
Score: 0.000
-
Analysis of signal transduction in B chronic lymphocytic leukemia cells. Blood. 1988 May; 71(5):1461-9.
Score: 0.000
-
Differential expression of MHC class II antigens in chronic B-cell disorders. Clin Exp Immunol. 1988 Feb; 71(2):217-23.
Score: 0.000
-
Allogeneic bone marrow transplantation. Recent developments and the potential expansion of the donor pool. Acta Oncol. 1988; 27(5):567-70.
Score: 0.000
-
Synergistic action of calcium ionophore A23187 and phorbol ester TPA on B-chronic lymphocytic leukemia cells. Blood. 1987 Nov; 70(5):1536-42.
Score: 0.000
-
Rapid recovery of helper activity following T cell depleted allogeneic marrow transplant. Clin Exp Immunol. 1987 Sep; 69(3):601-10.
Score: 0.000
-
CD5-positive B cells after T cell depleted bone marrow transplantation. Clin Exp Immunol. 1987 Jun; 68(3):662-8.
Score: 0.000
-
B cell development and regulation after T cell-depleted marrow transplantation. J Immunol. 1987 Apr 15; 138(8):2445-50.
Score: 0.000
-
Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy. Bone Marrow Transplant. 1987 Apr; 1(4):347-55.
Score: 0.000
-
Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts. Br J Cancer. 1987 Mar; 55(3):287-90.
Score: 0.000
-
Standardization of T-cell depletion in HLA matched bone marrow transplantation. Br J Haematol. 1986 Sep; 64(1):69-75.
Score: 0.000
-
Production of anti-cytomegalovirus antibody following T-cell depleted bone marrow transplant. Br J Haematol. 1986 Aug; 63(4):659-64.
Score: 0.000
-
Haemolysis after T-cell depleted bone marrow transplantation involving minor AB0 incompatibility. Scand J Haematol. 1986 Jul; 37(1):1-3.
Score: 0.000
-
Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol. 1986 Jun; 63(2):221-30.
Score: 0.000
-
T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. Clin Exp Immunol. 1986 Mar; 63(3):577-86.
Score: 0.000
-
Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Mar; 62(3):413-20.
Score: 0.000
-
Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986 Feb 15; 1(8477):339-43.
Score: 0.000
-
Human clones with natural killer function can activate B cells and secrete B cell differentiation factors. Eur J Immunol. 1985 Jun; 15(6):606-10.
Score: 0.000
-
Production of leucocyte interferon in vitro in children with recurrent respiratory infections. Lancet. 1984 Jun 02; 1(8388):1247.
Score: 0.000
-
Immunofluorescent studies of human leukemic cells with antiserum to a murine leukemic virus (Rauscher strain). Blood. 1968 Mar; 31(3):381-7.
Score: 0.000